Effect of Telmisartan on Cholesterol Levels in Patients with Hypertension - Saga Telmisartan Aggressive Research (STAR)

Abstract

Saga Telmisartan Aggressive Research (STAR) is a single-arm, prospective multi-center trial to evaluate the effectiveness of treatment with telmisartan in patients with hypertension. A total of 197 patients with a systolic blood pressure of ≥140 or a diastolic blood pressure of ≥90 mmHg were enrolled in this study, and were prescribed 20 to 80 mg/day of telmisartan for 6 months. In all patients, both systolic and diastolic blood pressures decreased (159±20 to 135±12 mmHg, p<0.0001, 87±12 to 75±8 mmHg, p<0.0001, respectively). In addition, total cholesterol (TC) levels decreased from 200±40 to 188±33 mg/dl (p<0.05). In patients with TC ≥220 mg/dl, the change was more striking (249±33 to 204±31 mg/dl, p<0.0001). Even in patients receiving statins, TC levels still were decreased (216±51 to 190±31 mg/dl, p<0.02). In addition, TC levels were also decreased even in patients receiving telmisartan in exchange for other ARBs with TC ≥220 mg/d. Triglyceride (TG) levels were decreased (270±199 to 175±74 mg/dl, p<0.005) in patients with TG levels ≥150 mg/dl. Fasting blood glucose (FBG) was decreased (158±68 to 138±60 mg/dl, p<0.05) in patients with FBG ≥110 mg/dl. These results suggest that telmisartan may have favorable effects on lipid and glucose metabolism, in addition to lowering blood pressure. The profound effect of telmisartan to lower cholesterol suggests a potential use in hypertensive patients with dyslipidemia.

telmisartan - hypertension - dyslipidemia - cholesterol

References

• 1 deGasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology, XXIII: the angiotensin II receptors.  Pharmacol Rev. 2000;  52 415-472
• 2 Wienen W, Entzeroth M, van Meel JC, Stangier J, Busch U, Ebner T, Schmid J, Lehmann H, Matzek K, Kempthorne-Rawson J, Gladigau V, Hauel NH. A review on telmisartan: a novel, long-acting angiotensin II-receptor antagonist.  Cardiovasc Drug Rev. 2000;  18 127-156
• 3 Sharpe M, Jarvis B, Goa KL. Telmisartan: a review of its use in hypertension.  Drugs. 2001;  61 1501-1529
• 4 Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity.  Hypertension. 2004;  43 993-1002
• 5 Schpp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferators-acyivated receptor-gamma activity.  Circulation. 2004;  109 2054-2057
• 6 Yamauchi T, Kamon J, Waki Y, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T. The fat-derived hormone adiponectin reserves insulin resistance associated with both lipoatrophy and obesity.  Nat Med. 2001;  7 941-946
• 7 Lehmann JM, Moore LB, Smith-Oliver TA, Wilkinson WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for proxisome proliferator-activated receptorγ (PPARγ).  J Biol Chem. 1995;  270 12953-12956
• 8 Wakino S, Law RE, Hsuch WA. Vascular protective effects by activation of nuclear receptor PPAR-γ.  J Diabetes Complicat. 2002;  16 46-49
• 9 Schiffrin EL, Amiri F, Benkirane K, Iglarz M, Diep QN. Peroxisome proliferator-activated receptors: vascular and cardiac effects in hypertension.  Hypertension. 2003;  42 664-668
• 10 Forst T, Hohberg C, Fuellert SD, Lubben G, Konrad T, Lobig M, Weber MM, Sachara C, Gottschall V, Pfutzner A. Pharmacological PPARgamma stimulation in contrast to beta cell stimulation results in an improvement in adiponectin and proinsulin intact levels and reduces intima media thickness in patients with type 2 diabetes.  Horm Metab Res. 2005;  37 521-527
• 11 Miura Y, Yamamoto N, Tsunekawa S, Taguchi S, Eguchi Y, Ozaki N, Oiso Y. Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes.  Diabetes Care. 2005;  28 737-738
• 12 Derosa G, Cicero AFG, Bertone G, Piccinni MN, Fogari E, Ciccarelli L, Fogari R. Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized, double-blind study.  Clin Ther. 2004;  26 1128-1236
• 13 Dormandy JA, Chabonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L, Laakso M, Mokan M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J. PRO active investigators . Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial.  Lancet. 2005;  366 1279-1289
• 14 Von Eckardstein A, Nofer J, Assmann G. High density lipoproteins and arteriosclerosis: role of cholesterol efflux and reverse cholesterol transport.  Arterioscler Thromb Vasc Biol. 2001;  21 13-27
• 15 Repa JJ, Turley SD, Lobaccaro JA, Medina J, Li L, Lustig K, Shan B, Heyman RA, Dietschy JM, Mangelsdorf DJ. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers.  Science. 2000;  289 24-29
• 16 Schupp M, Clemenz M, Gineste R, Wii H, Janke J, Hellebold S, Hennuyer N, Ruiz P, Unger T, Staels B, Kintscher U. Molecular characterization of new selective peroxisome proliferators-activated receptor γ modulators with angiotensine receptor blocking activity.  Diabetes. 2005;  54 3442-3452
• 17 Kurtz TW, Pravenec M. Antidiabetic mechanism of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists : beyond the renin-angiotensin system.  J Hypertens. 2004;  22 2253-2261

Appendix

The following physicians in Saga Medical Association, Japan, participated in the STAR trial: Masahiro Yoshiwara, Genichiro Edakuni, Ryutaro Yamaguchi, Taizo Minami, Masanori Nishiyama, Takanobu Nii, Mansei Matsunaga, Atsushi Sakai, Naoki Kojima, Akira Takahashi, Koichiro Furukawa, Makoto Tsuruta, Shunpo Uemura.

Correspondence